10x Genomics Ships First Atera Instruments as Demand Tops 2026 Target
TXG has more than doubled off its 52-week low of $11.16.
Summary
10x Genomics has begun global commercial shipments of Atera, its next-generation spatial biology platform, marking the first revenue-generating milestone for the product. Booked orders have already exceeded the 40 instruments the company expected to ship in 2026, and nearly all of the world's top 20 R&D-spending biopharma companies have purchased systems or services. Catalyst Research Services has booked projects across more than 100 customers in just five months, with meaningful biopharma participation. The ASTRA consortium plans to use Atera to expand its pan-cancer atlas from 2,000 to 5,000 tumors over the next two years. This launch follows a Q2 net loss of $17.9M and sluggish core product growth, making Atera's early demand a critical inflection point for the company's revenue trajectory. The stock is trading near its 52-week high, reflecting investor optimism about the platform's potential.
At the time of this announcement, TXG was trading at $89.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $11.16 to $89.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.